HCA Healthcare Announces Collaboration With Johnson & Johnson to Address Key Healthcare Clinical and Industry Issues
HCA Healthcare (NYSE: HCA) has announced a collaboration with Johnson & Johnson to tackle critical healthcare challenges. Key initiatives include a program for early-stage lung cancer detection in the Black community, integrating nursing resources to support nurses, and joint research on cardiovascular health. HCA utilizes data from over 35 million annual patient encounters for care improvement. This partnership aims to enhance health equity, patient outcomes, and nursing support, reflecting HCA's commitment to advancing healthcare quality.
- Collaboration with Johnson & Johnson aims to improve health equity and patient outcomes.
- Focus on early-stage lung cancer detection in the Black community.
- Integration of nursing resources to enhance support for over 93,000 nurses.
- None.
The two leading healthcare companies initially will focus on improving health equity, enhancing nursing support, and improving patient outcomes:
-
HCA Healthcare and Johnson & Johnson will collaborate on a scalable program to improve health outcomes through early-stage lung cancer detection for the Black community. Lung cancer is the number one cause of cancer death among Black patients1, and the two companies will begin to work together on a pilot program in the coming months to increase early identification. -
HCA Healthcare , which has more than 93,000 nurses in its system, and Johnson & Johnson have a long-standing commitment to advocating for and supporting nurses. The two healthcare leaders will work together to incorporate Johnson & Johnson’s nursing resources withinHCA Healthcare and its affiliateGalen College of Nursing . The companies will work together on health equity issues focused on educational programming, training and other programs that elevate and support nurses with a goal of enriching the nursing experience and skillsets and improving patient outcomes. -
HCA Healthcare , through itsHCA Healthcare Research Institute , and Johnson & Johnson will collaborate on cardiovascular health initiatives including a retrospective analysis of patients who suffer from heart arrhythmia, as well as research to understand the role digital health technology plays in impacting clinical outcomes for patients with Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD) diseases.
“HCA Healthcare and Johnson & Johnson have had a long and productive relationship, and both companies have worked very hard to address many of our country’s healthcare challenges,” said
“No one company can solve society’s most pressing health challenges alone -- it takes collaboration,” said
About
All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this document refer to
1
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005137/en/
INVESTOR CONTACT:
615-344-2688
MEDIA CONTACT:
615-344-1851
Source:
FAQ
What initiatives are HCA and Johnson & Johnson collaborating on?
When will HCA and Johnson & Johnson's pilot program for lung cancer detection start?
What is HCA's commitment in the healthcare industry?
How does HCA utilize patient data for care improvement?